Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Long-Term Investments (2021 - 2023)

Envoy Medical's Long-Term Investments history spans 3 years, with the latest figure at $44.6 million for Q2 2023.

  • On a quarterly basis, Long-Term Investments fell 89.51% to $44.6 million in Q2 2023 year-over-year; TTM through Jun 2023 was $44.6 million, a 89.51% decrease, with the full-year FY2022 number at $353731.0, down 99.92% from a year prior.
  • Long-Term Investments hit $44.6 million in Q2 2023 for Envoy Medical, up from $44.4 million in the prior quarter.
  • Over the last five years, Long-Term Investments for COCH hit a ceiling of $427.1 million in Q3 2022 and a floor of $353731.0 in Q4 2022.
  • Historically, Long-Term Investments has averaged $256.0 million across 3 years, with a median of $425.0 million in 2021.
  • Biggest five-year swings in Long-Term Investments: crashed 99.92% in 2022 and later crashed 89.51% in 2023.
  • Tracing COCH's Long-Term Investments over 3 years: stood at $425.0 million in 2021, then crashed by 99.92% to $353731.0 in 2022, then soared by 12521.29% to $44.6 million in 2023.
  • Business Quant data shows Long-Term Investments for COCH at $44.6 million in Q2 2023, $44.4 million in Q1 2023, and $353731.0 in Q4 2022.